SeraCare

Just Launched! ACCURUN® TV/MG Molecular Positive Control This control is designed as a ready-to-use quality control solution to monitor day-to-day performance of TV and MG molecular assays. Order your controls today by clicking this link: https://hubs.ly/Q0303ZKD0 #molecular #qualitycontrols #TVMG

New Blog Post! Infectious complications are a significant concern for patients after solid organ transplants. Molecular testing is a vital tool for the prevention of these complications. Read our latest blog "Managing Transplant Patient Health with Molecular Diagnostics" so you can ensure the accuracy of this critical information being placed in clinicians’ hands. https://hubs.ly/Q02_R3B-0 #moleculardiagnostics #infectiousdiseases #transplantorganhealth

Our posters from #AMP2024 are here! They showcase key advancements in critical areas like ctDNA validation, DPYD genetic testing for chemotherapy toxicity, and FFPE reference materials for NGS-based assays. These insights are addressing complex challenges and sparking meaningful discussions. These breakthroughs have the potential to directly impact your work in precision medicine and molecular diagnostics - Don't miss out! Access Posters: https://hubs.ly/Q02_fsGL0 #ctDNA #DPYD #FFPE #PrecisionMedicine #NextGenSequencing #GeneticTesting #LiquidBiopsy #Pharmacogenomics #CancerResearch

We are very excited to share this news with you, our loyal customers, colleagues, and followers.

Learn how you can play a key role in the success of transplant programs with our latest white paper - Enhancing the Care of Transplant Recipients with Infectious Disease Testing As demands continue to increase for transplants in the US and worldwide, consistent and reliable pre-transplant screening and post-transplant test methods are crucial to minimizing patient risk. Molecular diagnostic viral assays provide clinicians a non-invasive, dependable way to monitor this vital information. Download Now: https://hubs.ly/Q02-DQnD0 #Transplant #InfectiousTesting

New Product Announcement! We’re excited to introduce the Seraseq Solid Tumor FFPE DNA Reference Material, designed to address the challenges of #FFPE tissue samples in #GenomicProfiling. This material includes 74 biosynthetic DNA variants across 62 solid tumor-associated genes, featuring 37 SNVs, 18 deletions, 5 insertions, and 10 translocations. 65 of these variants are linked to FDA drug targets, offering a robust benchmark for clinical relevance. The material is provided in a lightly fixed FFPE format with clinically relevant allelic frequencies, ideal for testing assay sensitivity and detection limits. Learn more and access the complete table of mutations here: https://hubs.ly/Q02-rxx50 #CancerDiagnostics #DNASequencing #ClinicalGenomics #AssayDevelopment #CancerResearch

Thank you for an incredible #AMP2024 in Vancouver! It was an absolute pleasure connecting with so many of you and sharing the latest advancements in clinical genomics. Our workshop and posters sparked great discussions, and we’re thrilled by the positive feedback and engagement we received. Stay tuned—we'll be sharing all the details of the scientific posters presented at AMP very soon! The excitement continues!

Excited to share our 2024 AACR poster on optimizing DNA extraction from Formalin-Fixed Paraffin-Embedded (#FFPE) tissues, crucial for cancer diagnostics. Our refined extraction methods significantly improve DNA yield and integrity, enhancing Homologous Recombination Deficiency (#HRD) detection—a key biomarker for cancer treatment. Access the full poster here: https://hubs.ly/Q02ZJZ820 Stay tuned for our upcoming launch of Seraseq® Solid Tumor FFPE DNA Reference Material, designed to further boost genomic profiling accuracy for FFPE samples in cancer research. #AACR2024 #CancerDiagnostics #GenomicProfiling #DNAExtraction #CancerResearch #Biomarkers #NextGenSequencing #PrecisionMedicine #SolidTumor #CancerTreatment

In our latest Science Spotlight, we explore the paper "Analytical Validation of NeXT Personal, an Ultra-sensitive Personalized Circulating Tumor DNA Assay" published in Oncotarget In this paper, Personalis, Inc. describes NeXT Personal, an NGS-based assay for minimal residual disease (#MRD) monitoring of cancer recurrence following treatment. The team used the Seraseq ctDNA MRD Panel Mix for whole genome sequencing of tumor and matched normal gDNAs to mimic determination of a patient-specific mutation profile, then sequenced dilutions of ctDNA to detect those mutations at very low concentrations. This established positive and negative predictive values at 100%, indicating robust analytical accuracy. Access Article Here: https://hubs.ly/Q02Z81Yv0 #CancerResearch #ctDNA #Oncology #Genomics

Exciting news from #AMP24! It’s been a busy few days filled with fantastic workshops and presentations, and we’re looking forward to more great conversations. Join us at booth 1427 at LGC Clinical Diagnostics—our team of experts is on-site, eager to share insights and have meaningful discussions. Don’t miss out—come by and say hello!